Image-Only AI Model Outperforms Breast Density Assessment for 5-Year Breast Cancer Risk Stratification
An image-only artificial intelligence (AI) model demonstrated stronger and more precise risk stratification than breast density assessment for predicting 5-year risk for developing breast cancer, according to findings from a study presented at the 2025 Annual Meeting of the Radiological Society of North America (RSNA) (Abstract S5-SSBR02-1). The model, Clairity Breast, is the first U.S. Food and Drug Administration–authorized image-only AI breast cancer risk model.
Is Chronic Hepatitis C Infection Associated With Pancreatic Cancer?
A retrospective, national, population-based cohort study of 6.3 million veterans, which was published in JAMA Network Open, found that individuals with chronic hepatitis C virus developed pancreatic ductal adenocarcinoma at younger ages and had a higher risk compared with those without the infection. According to Levinson et al, risk also varied by virus genotype.
Addition of Neoadjuvant LuPSMA PNT2002 to SBRT in Oligorecurrent Prostate Cancer
In a single-center phase II trial (LUNAR) reported in the Journal of Clinical Oncology, Kishan et al found that the addition of neoadjuvant prostate-specific membrane antigen (PSMA)-targeting radioligand therapy with lutetium-177–labeled PNT2002 (LuPSMA PNT2002) to stereotactic body radiotherapy (SBRT) improved progression-free survival in patients with hormone-sensitive oligorecurrent prostate cancer.
Survey Finds Global Embrace of Integrative Cancer Care
Around the world, doctors, nurses, and pharmacists are turning to evidence-based integrative approaches such as acupuncture, yoga, exercise, massage, and nutrition counseling to help people with cancer manage the harsh side effects of treatment, according to the results of a recent survey.
Lung Cancer Screening Criteria: NELSON vs PLCOm2012
In a German study (HANSE) reported in The Lancet Oncology, Vogel-Claussen et al found that the PLCOm2012 low-dose computed tomography (CT) lung cancer screening eligibility criteria were more effective than the NELSON criteria in the detection of lung cancer.
Charles Bennett and colleagues: The Inflation Reduction Act and Ibrutinib
Derek Raghavan: How I Discuss the Current Political Chaos When Patients Ask Health-Related Questions About It
Narjust Florez and Coral Olazagasti: Silence Is Complicity
Robert Peter Gale: Therapy With a TKI for EGFR-Variant Lung Adenocarcinoma: Lessons From CML?
Raj Mohan on Kindness, Mercy, Empathy, Compassion: Are They Relevant in the Era of Robotics and AI?
Sponsored Content
SPONSORED BY LILLY MEDICAL AFFAIRS
Clinical Impact of Comprehensive Genomic Profiling in Early-Stage Non–Small Cell Lung Cancer
SPONSORED BY JOHNSON & JOHNSON
Evolving Treatment Landscape in First-Line EGFR-Mutant NSCLC: New Insights Into Combination TherapiesMore Top Stories
LuPSMA-617 Plus Hormone Therapy Improves Radiographic Progression–Free Survival in Metastatic Hormone-Naive Prostate Cancer
The addition of lutetium-177–labeled PSMA-617 (vipivotide tetraxetan; LuPSMA-617), a targeted radionuclide therapy, to standard-of-care androgen-deprivation therapy and an androgen receptor pathway inhibitor appeared to significantly improve radiographic progression–free survival in patients with...
FDA Grants Traditional Approval to Pirtobrutinib for CLL/SLL
On December 3, the U.S. Food and Drug Administration (FDA) granted traditional approval to pirtobrutinib (Jaypirca), a noncovalent Bruton’s tyrosine kinase (BTK) inhibitor, for adults with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) who have...
Ivonescimab, a Dual-Targeting Bispecific Antibody, Improves Progression-Free Survival in Squamous NSCLC
In the phase III HARMONi-6 trial, conducted in China, the bispecific antibody ivonescimab, given with chemotherapy, improved progression-free survival by 4.2 months over the PD-1 inhibitor tislelizumab-jsgr plus chemotherapy, a 40% reduction in risk as first-line treatment of advanced squamous...
Primary Analysis Shows Survival Benefit With Bemarituzumab Plus Chemotherapy in Gastric or Gastroesophageal Junction Cancer
The addition of bemarituzumab, a first-in-class anti-FGFR2b antibody, to mFOLFOX6 chemotherapy significantly improved overall survival in patients with FGFR2b-overexpressing (≥ 10% tumor cell staining) unresectable, locally advanced or metastatic gastric or gastroesophageal junction cancer,...
Lung Cancer Deaths Prevented and Life-Years Gained From Lung Cancer Screening: Current vs 100% Screening Uptake
In a study reported as a research letter in JAMA, Bandi et al compared estimated deaths prevented and life-years gained with current uptake vs 100% uptake of annual lung cancer screening in eligible U.S. individuals. Study Details The study used data obtained from the 2024 National Health Interview ...
Final Analysis Supports Use of Durvalumab Plus BCG Infusions in High-Risk Non–Muscle-Invasive Bladder Cancer
In patients with high-risk non–muscle-invasive bladder cancer, the addition of 1 year of the PD-L1 inhibitor durvalumab to standard induction and maintenance bacillus Calmette-Guérin (BCG) infusions led to a statistically significant and clinically meaningful improvement in disease-free survival...
Nivolumab and Ipilimumab in Advanced dMMR/MSI-H Noncolorectal Cancers
In an Australian and New Zealand phase II trial (MOST-CIRCUIT) reported in JAMA Oncology, Carlino et al found that combined anti–PD-1/CTLA-4 blockade was associated with a high rate of durable responses in patients with advanced mismatch repair–deficient/microsatellite instability–high (dMMR/MSI-H) ...
